Viser 322 virksomheder for "Pharmaceuticals"
Virksomheder
Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic drugs for rare and orphan diseases. They have a pipeline targeting various rare indications, including Netherton Syndrome. They plan to establish sales infrastructure in the US, Europe, and Japan and have marketing partnerships in 60 countries. They aim to bring hope to patients with unmet medical needs.
BioCorRx® is a healthcare solutions company focused on improving the lives of individuals struggling with alcohol, opioid, and other addictive disorders. Their Beat Addiction Recovery Program, utilized by treatment centers and physicians, combines cognitive behavioral therapy (CBT) with peer recovery support and may include medications for substance use disorders. BioCorRx Pharmaceuticals is developing treatments for opioid/alcohol use disorders.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. Their lead drug candidate, TPI 287, is an abeotaxane. The company focuses on aggressive brain cancers like glioblastoma multiforme (GBM). They aim to improve patient outcomes through pioneering research and transformative therapies.
GSK unites science, technology, and talent to get ahead of disease together. They focus on research and development in therapeutic areas like respiratory, immunology, oncology, and HIV. The company strives to improve global health through access to medicines and sustainable health systems.
Curida er en betroet CDMO med base i Norge, der tilbyder end-to-end udvikling og kontraktfremstilling af biologiske lægemidler samt sterile eller ikke-sterile flydende lægemidler. Med over 50 års ekspertise inden for Blow-Fill-Seal og næsespray-teknologier, understøtter vi alt fra formulering og teknologioverførsel til kommerciel opskalering. Vores Bio-CDMO enhed tilbyder fremstilling af monoklonale antistoffer til præklinisk og diagnostisk brug.
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs). They've developed proprietary ADC platforms (Dolasynthen and Immunosynthen) for treating various cancers. Their pipeline includes product candidates such as Emi-Le and XMT-2056, aiming to improve cancer treatment. Notably, Day One Biopharmaceuticals planned to acquire Mersana in late 2025.
XTL Biopharmaceuticals Ltd. focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company is publicly traded on the NASDAQ and the Tel-Aviv Stock Exchange. They are developing hCDR1 for the treatment of Systemic Lupus Erythematosus and Recombinant Erythropoietin for the treatment of multiple myeloma.
Agilera er en førende CDMO, der bidrager til teknologiudvikling og vækst på radiolægemiddelmarkedet. De tilbyder hele værdikæden for udvikling af nye radiolægemidler, fra den prækliniske fase til kommerciel produktion og global distribution. Agilera er godkendt som producent for USA, Japan, Europa, Latinamerika og Kina.
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal (GI) diseases, particularly acid-related disorders. They have licensed exclusive rights in the United States, Europe, and Canada to a potassium-competitive acid blocker (PCAB). Phathom is committed to transforming the treatment landscape and improving the lives of patients.
Clover Biopharmaceuticals develops and commercializes innovative vaccines using their proprietary Trimer-Tag technology. Committed to improving global health, they focus on vaccine development, manufacturing, and global partnerships to combat infectious diseases.
INmune Bio Inc. is a clinical stage biotechnology company developing immunotherapies that reprogram the innate immune system to fight cancer and Alzheimer's. They develop novel therapies targeting distinct parts of a patient’s innate immune system. Drug candidates, INKmune™ and INB03, may be used to treat cancer, while XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. They utilize a precision therapy approach to treat unsolved problems in medicine.
Enanta Pharmaceuticals is a clinical stage biotechnology company focused on creating oral drugs for virology and immunology. They are known for their collaboration with AbbVie, which resulted in two protease inhibitors used in chronic hepatitis C treatment. Their current research focuses on respiratory syncytial virus (RSV) and immunology treatments for inflammatory diseases.
Candel Therapeutics is developing viral immunotherapies designed to educate the immune system to recognize and eliminate cancer cells. Their approach combines an anti-tumor component with an immune-stimulatory component, leading to an “in-situ immunization” effect against the injected tumor and uninjected metastases. They aim to improve survival while maintaining quality of life.
ACD Pharma er en norsk R&D-virksomhed, der udvikler biokontrolprodukter baseret på bakteriofager. Virksomheden var oprindeligt fokuseret på akvakultur, men har udvidet til at bekæmpe skadelige bakterier hos dyr og mennesker. I 2018 lancerede ACD Pharma Custus®YRS, verdens første bakteriofagprodukt til akvakultur. De samarbejder med farmaceutiske og videnskabelige teams om at anvende bakteriofager mod antibiotikaresistens.
SciSparc is a specialty pharmaceutical company developing unique cannabinoid technologies for the treatment of central nervous system disorders. They have several drug candidates in clinical trials, targeting conditions like Tourette Syndrome and Alzheimer's. The company boasts an established management team and a scientific advisory board chaired by Professor Raphael Mechoulam.
Scilex Holding Company is an innovative company focused on developing and commercializing non-opioid pain management products. They aim to become a global leader in pain management. Their lead product is ZTlido®, a prescription lidocaine topical system. They have also acquired GLOPERBA® and ELYXYB®, non-opioid pain products.
Adicet Bio is a biotechnology company focused on gamma delta T cell therapies for autoimmune diseases and cancer. They aim to deliver best-in-class allogeneic cell therapies. Their novel platform allows for novel targeting, tissue homing, and best-in-class drug exposure, available on demand.
CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Their key product, DefenCath®, is designed to prevent catheter-related bloodstream infections (CRBSI). The company is positioned as an innovator in infection prevention.
Aktis Oncology is pioneering a new class of targeted radiopharmaceuticals to improve outcomes for cancer patients. They have built a proprietary miniprotein radioconjugate platform designed to safely confer breakthrough efficacy for broad patient populations with unmet needs. Their focus is on prevalent tumor types historically beyond the reach of radiopharmaceuticals, developing next-generation precision treatments.
Hikma is a global pharmaceutical company that develops, manufactures, and markets a broad range of generic and branded pharmaceuticals. They focus on injectable products, as well as prescription and over-the-counter medicines. Hikma has established itself as a significant player in pharmaceutical manufacturing and contract manufacturing.